UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

29 New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Read More Share:

Aug

30 UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Read More Share:

Aug

07 New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Read More Share:

Apr

28 UCB Announces PDUFA Date for Bimekizumab

Read More Share:

Apr

23 "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Read More Share:

Apr

23 UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Read More Share:

Apr

16 UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Read More Share:

Feb

25 UCB - Sustaining Growth, Now and Into the Future

Read More Share:

Feb

23 UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Read More Share:

Feb

05 The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Read More Share:

Categories

Archives

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Aug

07

New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Apr

16

UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Feb

23

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Notice about cookies

Categories

Archives

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Aug

07

New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Apr

16

UCB Showcases New Research at the 73rd American Academy of Neurology Annual Meeting to Demonstrate Broad Neurology Leadership and Future Portfolio

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Feb

23

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact